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References Types of stem cell 
infused
Number of patients Improvement after cell infusion
Mesenchymal stem cells
Zhang Z, et al., J Gastroenterol Hepatol, 2012 Umbilical cord-MSC 30 treatment, 
15 control
Improved liver function, MELD and reduced ascites
Shi M, et al., Stem Cell Transl Med, 2012 Umbilical cord-MSC 24 treatment, 
19 control
Improved liver function, MELD and reduced survival rates
MoHamadnejad M, et al., Arch Iran Med, 2007 BM-MSC 3 cryptogenic, 
1 AIH
Improved MELD
Kharaziha P, et al., Eur J Gastroenterol Hepatol, 2009 BM-MSC 4 HBV, 1 HCV, 
1 alcoholic, 2 cryptogenic
Improved MELD and liver function
Peng, et al., Hepatology, 2011 BM-MSC 53 treatment, 
105 control
Improved ALB, TBIL and MELD
Bone marrow-derived precursors
Lyra AC, et al., World J Gastroenterol, 2007 BMNC 3 HCV, 3 alcoholic, 
4 others cryptogenic
Decreased TBIL and INR and improved ALB
Amer, et al., Eur J Gastroenterol Hepatol, 2011 BMNC 10 intrasplenic, 
10 intrahepatic, 20 control
Improved ascites and MELD
Terai S, et al., Stem cell, 2006 BMNC 5 HCV, 3 HBV, 1 unknown Improved ALB and CP
Kim JK, et al., Cell Transpl, 2012 BMNC 10 HBV Increased liver volume and CP score
Saito T, et al., Stem Cell Dev, 2011 BMNC 5 treatment, 5 control Improved ALB, PT and CP score
Lyra AC, et al., Gut, 2 007 BMNC 15 treatment, 15 control Improved ALB and CP score
Hematopoietic stem cells
Gordon MY, et al., Stem Cells, 2006 CD34+ cells 5 treatment Improved ALB
MoHamadnejad M, et al., World J Gastroenterol, 2007 CD34+ cells 1 HBV, 1 AIH, 1 PBC, 
1 cryptogenic 
Improved MELD
Pai M, et al., Am J Gastroenterol, 2008 Cultured 
CD34+ cells 
9 treatment Improved ALB and CP score
Garg V, et al., Gastroenterol, 2012 G-CSF mobilized 
CD34+ cells
23 treatment, 24 placebo Increased survival, reduced MELD scores
Han Y, et al., Cytotherapy, 2008 PBMCs from G-CSF 
mobilized PB
20 treatment, 20 control Improved ALB and CP score
Am Esch JS, et al., Stem Cells, 2005 CD133+ cells 3 treatment, 3 control Improved liver volume after liver resection
MSC, mesenchymal stem cell; BMNC, bone marrow mononuclear cells; PB, peripheral blood; G-CSF, granulocyte colony-stimulating factor; CP, Child-Pugh score; MELD, model for end-
stage liver disease; AIH, autoimmune hepatitis.
Table. Clinical study using stem cells/MSC treatment for patients with liver failure or cirrhosis.Introduction
Liver failure and cirrhosis occur as a result of a variety of chronic 
hepatic injuries. They display sequential and overlapping severe 
pathogenic processes that include severe inflammation, hepatocyte 
necrosis, and fibrosis/cirrhosis, and carry a high mortality rate [1]. 
There is a prevailing contradiction between the urgent need for liver 
transplants and a severe shortage of donor livers, which highlights 
the need to develop new therapeutic strategies for these conditions. 
Recent studies have shown that stem cell-based therapies may reduce 
liver inflammation, and subsequently improve scarring and replenish 
hepatocytes, which could be a promising strategy for patients with 
liver failure and cirrhosis [2]. By November 1st, 2012, more than 170 
clinical trials had been registered or were in proof when ClinicalTrials.
gov was searched for the terms “stem cells AND liver diseases”. In 
particular, mesenchymal stem cells (MSCs) are a heterogeneous 
subset of stromal stem cells that mainly express CD105, CD73, CD44, 
CD90, and CD71, rather than hematopoietic markers such as CD45, 
CD34, and CD14, or co-stimulatory molecules, such as CD80 and 
CD86. They can be obtained from a variety of tissues including bone 
marrow, adipose tissue, placenta, and Wharton jelly of the umbilical 
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Fig. Stem cell therapies for liver failure and cirrhosis. (A) The rationalization for stem c
massive inflammation and necrosis, and the accumulation of scar tissue, respectively (1). Dif
endowed with immunomodulatory (2), anti-fibrotic and pro-regenerative capabilities (3), which
and fibrotic hepatic microenvironments (4). Thus, ES-iPS could help expand the population
failure and cirrhosis. (B) The tailoring of stem cell co-transplantation towards patients with di
failure and cirrhosis. Precise clinical protocols need to be refined and translated into well-de
the selection of the optimal stem cell type, the number of infused stem cells, the route of adcord. Importantly, MSCs can not only differentiate into cells of the 
mesodermal lineage and other embryonic lineages, but can also 
functionally mediate immune modulation in vivo [3]. The administration 
of MSCs in small-sample size clinical trials has also been reported to 
be well tolerated and safe, and confers beneficial effects in patients 
with liver failure, by enhancing liver function and reducing Child-Pugh 
and MELD scores, ascites, and overall mortality (Table) [4–8]. However, 
some concerns and critical issues remain unanswered regarding the 
long-term safety and efficacy of clinical stem cell therapies.
 Rationalization for stem cell therapies
Improvements in hepatic inflammatory and fibrotic microenvironments
In patients with liver failure or cirrhosis, inflammation-associated liver 
damage and fibrosis are usually mediated by abnormal innate and 
adaptive immune responses. Although many details of the involvement 
of MSCs with inflammatory and fibrotic processes remain unknown, 
MSCs have been demonstrated to play an immunomodulatory role 
through producing inhibitory cytokines or inducing the development of 
regulatory T cells [9]. Interestingly, MSC therapy appears to be effective 
013 vol. 59 | 183-185
ell therapies in liver failure and cirrhosis. Liver failure and cirrhosis are characterized by 
ferent stem cell types and their progenies have various putative functional roles. MSCs are 
 can support the expansion of regenerating hepatocytes via ameliorating the inflammatory 
 of functional hepatocytes (5), ultimately improving the liver function of patients with liver 
fferent types and stages of liver disease may offer novel therapeutic interventions for liver 
signed, randomized controlled clinical trials that are double-blinded. These would optimize 
ministration, timing of interventions and the selection of suitable fixed primary end points.
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in regulating the immune response in tissue injury, transplantation, 
and autoimmunity in both animal models of liver disease and patients 
in clinical trials [3]. MSCs can also directly inhibit the activation of 
hepatic stellate cells (HSCs), the main cell source of the extracellular 
matrix, via MSC-derived IL-10 and TNF-α, and may also induce HSC 
apoptosis via, in part, the Fas/FasL pathway [10]. Notably, MSCs 
have the potential to differentiate into myofibroblasts, which act as 
scar-forming cells within the liver in certain settings. Recent findings 
showed that use of whole bone marrow as a cell therapy in a rodent 
model with chronic liver injury led to the development of hepatic fibrosis 
[11]. Thus, MSCs are considered to act through multiple mechanisms 
to coordinate a dynamic, integrated response to liver inflammation 
and fibrosis, which prevents the progressive distortion of hepatic 
architecture (see Figure, panel A).
Replenish functional hepatocytes
Another realistic target of MSC therapy is to replace damaged 
hepatocytes with exogenous functional hepatocytes in patients with 
liver failure or cirrhosis. In this regard, embryonic stem (ES) cells 
and induced pluripotent stem (iPS) cells have been shown to be the 
most capable of producing large numbers of functional hepatocyte-
like cells (HLCs) in both mice and humans. However, ethical issues 
and uncertainties regarding their behavior in vivo in an appropriate 
homoeostatic manner have limited their clinical implications [12] 
(see Figure, panel A). The amelioration of hepatic inflammatory and 
fibrotic microenvironments via stem cell therapy is likely to promote the 
generation of residual hepatocytes. In particular, recent studies have 
indicated that MSCs can produce various growth factors and cytokines, 
such as hepatocyte growth factor, which exerts a protective role 
against liver injury and is critical for hepatic regeneration [5,13] (see 
Figure, panel A). However, it remains to be explored whether and how 
MSCs can promote liver stem cells to differentiate into hepatocytes or 
expand the residual hepatocyte population to obtain sufficient numbers 
and quality in vivo for patients with liver diseases. In addition, future 
studies will need to demonstrate whether stem cell-derived HLCs 
have the same functionality in vivo as endogenous hepatocytes, and 
ensure that these cells cannot revert to a more primitive state within 
the recipient.
Current challenges
Several critical issues in clinical protocols require further investigation, 
such as the optimal type of transfused MSCs, the optimal therapeutic 
timing, the most effective number of stem cells, the best route of 
administration and the primary end points (see Figure, panel B). The  
long-term clinical benefits and safety of stem cell-based therapies 
should be further confirmed in a large-sized randomized controlled trial. 
It is currently unknown whether MSC therapy could induce complications 
such as hepatic artery dissection, tumorigenesis, and fibrogenesis. 
Additionally, it will be important to document the histological alterations 
caused by transplanted MSCs in order to track the fate of the infused 
stem cells in vivo, and to elucidate the mechanisms that underlie the 
bidirectional interactions between infused stem cells and the hepatic 
inflammatory/fibrotic microenvironments [14]. If these challenges can 
be resolved, the clinical application of stem cells for the treatment of 
patients with liver disease, with controllable and feasible standards 
and recommendations, will be further warranted.
Perspective and strategies
Stem cell therapies present an exciting but challenging frontier in 
translational hepatology. For patients with liver failure or cirrhosis, iPS/
ES cells may be excellent candidates for the production of functional 
hepatocytes to replenish deficient liver functions. MSCs appear to be 
the optimal candidates to ameliorate hepatic fibrotic and inflammatory 
microenvironments. Thus, the co-transplantation of iPS/ES-derived 
HLCs and MSCs may offer the potential for a range of new therapeutic 
interventions for liver disease (see Figure, panel B). Notably, liver 
failure and cirrhosis have variable pathogenic properties and disease 
severities. Considering the variable characteristics of different stem 
cells (ES, iPS, and MSCs), it will be highly important to tailor future 
stem cell therapies to specific patient types.
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